Molecular predictors of response to first-line systemic therapies in advanced hepatocellular carcinoma.

被引：0
|
作者：
Chang, Jeremy
Conner, Elizabeth
Fowler, Kathryn J.
Tamayo, Pablo
Burgoyne, Adam
机构：
[1] Univ Calif San Diego, La Jolla, CA USA
[2] Univ Calif San Diego, San Diego, CA USA
[3] Univ Calif San Diego, Dept Radiol, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-566-9263; 261-566-3248-9542-427-2615; 130-540-543-4790; 3282-270-11593; 283-424-425; 261-566-11347; 3282-206-3691-2722; 8; 6; 4; 3; 1854; 182; 7; 38092-33627; 38092-29187; 38092-20072; 38092-21191; 38092-34303; 2; 1;
D O I：
10.1200/JCO.2024.42.3_suppl.534
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：534 / 534
页数：1
相关论文
共 50 条
  • [21] Risk of proteinuria with atezolizumab plus bevacizumab versus lenvatinib in first-line systemic treatment for hepatocellular carcinoma.
    Yang, JIwon
    Choi, Won-Mook
    Kim, Hyung-Don
    Choi, Jonggi
    Yoo, Changhoon
    Lee, Danbi
    Shim, Ju Hyun
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 558 - 558
  • [22] Regorafenib plus tislelizumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma (HCC)
    Chuang, Chienhuai
    Liu, Tsung-Hao
    Hsu, Meng-Chi
    Chang, Mo-Jung
    Cheng, Ann-Lii
    Hsu, Chiun
    ANNALS OF ONCOLOGY, 2023, 34 : S1398 - S1398
  • [23] A change in the timing for starting systemic therapies for hepatocellular carcinoma : the comparison of sorafenib and lenvatinib as the first-line treatment
    Hatanaka, T.
    Kakizaki, S.
    Nagashima, T.
    Ueno, T.
    Namikawa, M.
    Tojima, H.
    Takizawa, D.
    Naganuma, A.
    Arai, H.
    Sato, K.
    Harimoto, N.
    Shirabe, K.
    Uraoka, T.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2021, 84 (01) : 65 - 72
  • [24] Insights into the future of first-line advanced hepatocellular carcinoma treatment
    Wong, Jeffrey Sum Lung
    Wong, Carmen Chak-Lui
    Sun, Frances Sze Kei
    Yau, Thomas
    LANCET ONCOLOGY, 2025, 26 (02): : 152 - 153
  • [25] Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond
    Feng, Maple Ye
    Chan, Landon L.
    Chan, Stephen Lam
    CURRENT ONCOLOGY, 2022, 29 (08) : 5489 - 5507
  • [26] Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
    Persano, M.
    Rimini, M.
    Tada, T.
    Suda, G.
    Shimose, S.
    Kudo, M.
    Cheon, J.
    Finkelmeier, F.
    Presa, J.
    Masi, G.
    Yoo, C.
    Lonardi, S.
    Piscaglia, F.
    Iavarone, M. A.
    Tamburini, E.
    Cabibbo, G.
    Silletta, M.
    Cascinu, S.
    Scartozzi, M.
    Gardini, A. Casadei
    ANNALS OF ONCOLOGY, 2023, 34 : S603 - S604
  • [27] First-line targ veted therapies of advanced hepatocellular carcinoma: A Bayesian network analysis of randomized controlled trials
    Ding, Wei
    Tan, Yulin
    Qian, Yan
    Xue, Wenbo
    Wang, Yibo
    Jiang, Peng
    Xu, Xuezhong
    PLOS ONE, 2020, 15 (03):
  • [28] PHARMACOECONOMIC EVALUATION OF SORAFENIB AS FIRST-LINE TREATMENT FOR ADVANCED HEPATOCELLULAR CARCINOMA
    Naumovska, Z.
    Nestorovska, Kapedanovska A.
    Grozdanova, A.
    Suturkova, L.
    Dimovski, A.
    Sterjev, Z.
    VALUE IN HEALTH, 2017, 20 (09) : A736 - A736
  • [29] Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies
    Fareau, Gilbert G.
    Lopez, Adriana
    Stava, Charles
    Vassilopoulou-Sellin, Rena
    ANTI-CANCER DRUGS, 2008, 19 (06) : 637 - 644
  • [30] Novel systemic therapies in hard to treat fibrolamellar hepatocellular carcinoma.
    Gliksberg, Ariel
    O'Grady, Claire
    Kent, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345